40,30 €
6,82 % vorgestern
L&S, 6. Februar, 22:54 Uhr
ISIN
US80706P1030
Symbol
SRRK
Berichte

Scholar Rock Holding Corp. Aktie News

Positiv
The Motley Fool
8 Tage alt
Mo Qatanani sold 14,898 shares directly for a transaction value of approximately $695,938 on Jan. 22, 2026, at a weighted average price of $46.71 per share. The sale represented 14.82% of Qatanani's direct holdings, reducing direct ownership to 85,660 shares, which equates to 0.08% of shares outstanding.
Neutral
Business Wire
23 Tage alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,...
Neutral
Seeking Alpha
27 Tage alt
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral
Business Wire
27 Tage alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today provided a corporate update an...
Positiv
Seeking Alpha
etwa ein Monat alt
I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expa...
Neutral
Business Wire
etwa ein Monat alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will...
Neutral
Business Wire
etwa 2 Monate alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,34...
Neutral
Seeking Alpha
2 Monate alt
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen